Emergency Use Authorization of Remdesivir
Michael G. Ison, Cameron R. Wolfe, Helen W. Boucher
Abstract
This Viewpoint reviews the FDA’s May 2020 Emergency Use Authorization of the antiviral drug remdesivir for treatment of COVID-19 and discusses the need for a transparent distribution plan of a drug not otherwise available in the US and for which demand will likely exceed supply.
Topics & Concepts
MedicineAuthorizationCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakMedical emergencyDrugIntensive care medicineVirologyPharmacologyComputer securityPathologyInfectious disease (medical specialty)DiseaseComputer scienceOutbreakInfluenza Virus Research StudiesDrug-Induced Hepatotoxicity and ProtectionHepatitis C virus research